Advertisement

Neurocritical Care

, Volume 29, Issue 3, pp 344–357 | Cite as

Stress Ulcer Prophylaxis in Neurocritical Care

  • Jeffrey F. Barletta
  • Alicia J. Mangram
  • Joseph F. Sucher
  • Victor Zach
Review Article

Abstract

Stress ulcer prophylaxis (SUP) with acid-suppressive drug therapy is widely utilized in critically ill patients following neurologic injury for the prevention of clinically important stress-related gastrointestinal bleeding (CIB). Data supporting SUP, however, largely originates from studies conducted during an era where practices were vastly different than what is considered routine by today’s standard. This is particularly true in neurocritical care patients. In fact, the routine provision of SUP has been challenged due to an increasing prevalence of adverse drug events with acid-suppressive therapy and the perception that CIB rates are sparse. This narrative review will discuss current controversies with SUP as they apply to neurocritical care patients. Specifically, the pathophysiology, prevalence, and risk factors for CIB along with the comparative efficacy, safety, and cost-effectiveness of acid-suppressive therapy will be described.

Keywords

Stress ulcer prophylaxis Acid-suppressive therapy Proton pump inhibitors Histamine-2-receptor antagonists Gastrointestinal hemorrhage Adverse drug events Neurocritical care 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347–79.Google Scholar
  2. 2.
    Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002;30(6 Suppl):S351–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Lucas CE, Sugawa C, Riddle J, Rector F, Rosenberg B, Walt AJ. Natural history and surgical dilemma of “stress” gastric bleeding. Arch Surg. 1971;102(4):266–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Cushing H. Peptic ulcers and the interbrain. Surg Gynecol Obstet. 1932;55:1–34.Google Scholar
  5. 5.
    Cheung LY. Pathogenesis, prophylaxis, and treatment of stress gastritis. Am J Surg. 1988;156(6):437–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 1994;330(6):377–81. doi: 10.1056/nejm199402103300601.CrossRefPubMedGoogle Scholar
  7. 7.
    Idjadi F, Robbins R, Stahl WM, Essiet G. Prospective study of gastric secretion in stressed patients with intracranial injury. J Trauma. 1971;11(8):681–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Rumalla K, Mittal MK. Gastrointestinal bleeding in acute ischemic stroke: a population-based analysis of hospitalizations in the United States. J Stroke Cerebrovasc Dis. 2016;25(7):1728–35. doi: 10.1016/j.jstrokecerebrovasdis.2016.03.044.CrossRefPubMedGoogle Scholar
  9. 9.
    Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51. doi: 10.1056/NEJMoa011258.CrossRefPubMedGoogle Scholar
  10. 10.
    El Masri WE, Cochrane P, Silver JR. Gastrointestinal bleeding in patients with acute spinal injuries. Injury. 1982;14(2):162–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Epstein N, Hood DC, Ransohoff J. Gastrointestinal bleeding in patients with spinal cord trauma. Effects of steroids, cimetidine, and mini-dose heparin. J Neurosurg. 1981;54(1):16–20. doi: 10.3171/jns.1981.54.1.0016.CrossRefPubMedGoogle Scholar
  12. 12.
    Gore RM, Mintzer RA, Calenoff L. Gastrointestinal complications of spinal cord injury. Spine. 1981;6(6):538–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Kiwerski J. Bleeding from the alimentary canal during the management of spinal cord injury patients. Paraplegia. 1986;24(2):92–6. doi: 10.1038/sc.1986.12.CrossRefPubMedGoogle Scholar
  14. 14.
    Kuric J, Lucas CE, Ledgerwood AM, Kiraly A, Salciccioli GG, Sugawa C. Nutritional support: a prophylaxis against stress bleeding after spinal cord injury. Paraplegia. 1989;27(2):140–5. doi: 10.1038/sc.1989.21.CrossRefPubMedGoogle Scholar
  15. 15.
    Walters K, Silver JR. Gastrointestinal bleeding in patients with acute spinal injuries. Int Rehabil Med. 1986;8(1):44–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Leramo OB, Tator CH, Hudson AR. Massive gastroduodenal hemorrhage and perforation in acute spinal cord injury. Surg Neurol. 1982;17(3):186–90.CrossRefPubMedGoogle Scholar
  17. 17.
    Burgess P, Larson GM, Davidson P, Brown J, Metz CA. Effect of ranitidine on intragastric pH and stress-related upper gastrointestinal bleeding in patients with severe head injury. Dig Dis Sci. 1995;40(3):645–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Gudeman SK, Wheeler CB, Miller JD, Halloran LG, Becker DP. Gastric secretory and mucosal injury response to severe head trauma. Neurosurgery. 1983;12(2):175–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Halloran LG, Zfass AM, Gayle WE, Wheeler CB, Miller JD. Prevention of acute gastrointestinal complications after severe head injury: a controlled trial of cimetidine prophylaxis. Am J Surg. 1980;139(1):44–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Kamada T, Fusamoto H, Kawano S, Noguchi M, Hiramatsu K. Gastrointestinal bleeding following head injury: a clinical study of 433 cases. J Trauma. 1977;17(1):44–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Metz CA, Livingston DH, Smith JS, Larson GM, Wilson TH. Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind, randomized trial. Crit Care Med. 1993;21(12):1844–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Moller MH. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med. 2015;41(5):833–45. doi: 10.1007/s00134-015-3725-1.CrossRefPubMedGoogle Scholar
  23. 23.
    Chan KH, Mann KS, Lai EC, Ngan J, Tuen H, Yue CP. Factors influencing the development of gastrointestinal complications after neurosurgery: results of multivariate analysis. Neurosurgery. 1989;25(3):378–82.CrossRefPubMedGoogle Scholar
  24. 24.
    Misra UK, Kalita J, Pandey S, Mandal SK. Predictors of gastrointestinal bleeding in acute intracerebral haemorrhage. J Neurol Sci. 2003;208(1–2):25–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu BL, Li B, Zhang X, Fei Z, Hu SJ, Lin W, Gao DK, Zhang L. A randomized controlled study comparing omeprazole and cimetidine for the prophylaxis of stress-related upper gastrointestinal bleeding in patients with intracerebral hemorrhage. J Neurosurg. 2013;118(1):115–20. doi: 10.3171/2012.9.jns12170.CrossRefPubMedGoogle Scholar
  26. 26.
    Hatton J, Lu WY, Rhoney DH, Tibbs PA, Dempsey RJ, Young B. A step-wise protocol for stress ulcer prophylaxis in the neurosurgical intensive care unit. Surg Neurol. 1996;46(5):493–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Li ZM, Wang LX, Jiang LC, Zhu JX, Geng FY, Qiang F. Relationship between plasma cortisol levels and stress ulcer following acute and severe head injury. Med Princ Pract. 2010;19(1):17–21. doi: 10.1159/000252829.CrossRefPubMedGoogle Scholar
  28. 28.
    Cook D, Heyland D, Griffith L, Cook R, Marshall J, Pagliarello J. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Crit Care Med. 1999;27(12):2812–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Ellison RT, Perez-Perez G, Welsh CH, Blaser MJ, Riester KA, Cross AS, Donta ST, Peduzzi P. Risk factors for upper gastrointestinal bleeding in intensive care unit patients: role of helicobacter pylori. Crit Care Med. 1996;24(12):1974–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Guillamondegui OD, Gunter OL, Bonadies JA, Coates JE, Kurek SJ, DeMoya MA, Sing RF, Sori AJ. Practice management guidelines for stress ulcer prophylaxis. 2008. www.east.org. Accessed 24 Aug 2015.
  31. 31.
    Simons RK, Hoyt DB, Winchell RJ, Holbrook T, Eastman AB. A risk analysis of stress ulceration after trauma. J Trauma. 1995;39(2):289–93 (discussion 293-284).CrossRefPubMedGoogle Scholar
  32. 32.
    Barletta JF, Kanji S, MacLaren R, Lat I, Erstad BL. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. J Crit Care. 2014;29(6):955–60. doi: 10.1016/j.jcrc.2014.06.025.CrossRefPubMedGoogle Scholar
  33. 33.
    Barletta JF, Erstad BL, Fortune JB. Stress ulcer prophylaxis in trauma patients. Crit Care. 2002;6(6):526–30.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004;32(10):2008–13.CrossRefPubMedGoogle Scholar
  35. 35.
    Eastwood GM, Litton E, Bellomo R, Bailey MJ, Festa M, Beasley RW, Young PJ. Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units. Crit Care Resusc. 2014;16(3):170–4.PubMedGoogle Scholar
  36. 36.
    Erstad BL, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Crit Care. 1999;3(6):145–9. doi: 10.1186/cc368.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Gratrix AP, Enright SM, O’Beirne HA. A survey of stress ulcer prophylaxis in Intensive Care Units in the UK. Anaesthesia. 2007;62(4):421–2. doi: 10.1111/j.1365-2044.2007.05050.x.CrossRefPubMedGoogle Scholar
  38. 38.
    Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Moller MH. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiol Scand. 2015;59(5):576–85. doi: 10.1111/aas.12508.CrossRefPubMedGoogle Scholar
  39. 39.
    Lam NP, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med. 1999;27(1):98–103.CrossRefPubMedGoogle Scholar
  40. 40.
    Preslaski CR, Mueller SW, Kiser TH, Fish DN, MacLaren R. A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit. J Clin Pharm Ther. 2014;39(6):658–62. doi: 10.1111/jcpt.12208.CrossRefPubMedGoogle Scholar
  41. 41.
    Shears M, Alhazzani W, Marshall JC, Muscedere J, Hall R, English SW, Dodek PM, Lauzier F, Kanji S, Duffett M, Barletta J, Alshahrani M, Arabi Y, Deane A, Cook DJ. Stress ulcer prophylaxis in critical illness: a Canadian survey. Can J Anaesth. 2016;63(6):718–24. doi: 10.1007/s12630-016-0612-3.CrossRefPubMedGoogle Scholar
  42. 42.
    Brophy GM, Brackbill ML, Bidwell KL, Brophy DF. Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients. Neurocrit Care. 2010;13(2):176–81. doi: 10.1007/s12028-010-9397-3.CrossRefPubMedGoogle Scholar
  43. 43.
    Chan KH, Lai EC, Tuen H, Ngan JH, Mok F, Fan YW, Fung CF, Yu WC. Prospective double-blind placebo-controlled randomized trial on the use of ranitidine in preventing postoperative gastroduodenal complications in high-risk neurosurgical patients. J Neurosurg. 1995;82(3):413–7. doi: 10.3171/jns.1995.82.3.0413.CrossRefPubMedGoogle Scholar
  44. 44.
    Lee TH, Hung FM, Yang LH. Comparison of the efficacy of esomeprazole and famotidine against stress ulcers in a neurosurgical intensive car unit. Adv Dig Med. 2014;1:50–3.CrossRefGoogle Scholar
  45. 45.
    Misra UK, Kalita J, Pandey S, Mandal SK, Srivastava M. A randomized placebo controlled trial of ranitidine versus sucralfate in patients with spontaneous intracerebral hemorrhage for prevention of gastric hemorrhage. J Neurol Sci. 2005;239(1):5–10. doi: 10.1016/j.jns.2005.07.011.CrossRefPubMedGoogle Scholar
  46. 46.
    Reusser P, Gyr K, Scheidegger D, Buchmann B, Buser M, Zimmerli W. Prospective endoscopic study of stress erosions and ulcers in critically ill neurosurgical patients: current incidence and effect of acid-reducing prophylaxis. Crit Care Med. 1990;18(3):270–4.CrossRefPubMedGoogle Scholar
  47. 47.
    Liu B, Liu S, Yin A, Siddiqi J. Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2015;19:409. doi: 10.1186/s13054-015-1107-2.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, Bagin RG, Rock JA, Hepburn B, Laine L. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med. 2005;33(4):760–5.CrossRefPubMedGoogle Scholar
  49. 49.
    Kantorova I, Svoboda P, Scheer P, Doubek J, Rehorkova D, Bosakova H, Ochmann J. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004;51(57):757–61.PubMedGoogle Scholar
  50. 50.
    Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997;42(6):1255–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Solouki M, Marashian S, Kouchak M. Comparison between the preventive effects of ranitidine and omeprazole on upper gastrointestinal bleeding among ICU patients. Tanaffos. 2009;8:37–42.Google Scholar
  52. 52.
    Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, Wood G, Kirby A. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338(12):791–7. doi: 10.1056/nejm199803193381203.CrossRefPubMedGoogle Scholar
  53. 53.
    Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693–705. doi: 10.1097/CCM.0b013e3182758734.CrossRefPubMedGoogle Scholar
  54. 54.
    Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, Thabane L, Al-Omari A, Lewis K, Guyatt G, Alhazzani W. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):120. doi: 10.1186/s13054-016-1305-6.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–20. doi: 10.1038/ajg.2011.474 (quiz 521).CrossRefPubMedGoogle Scholar
  56. 56.
    Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010;38(4):1197–205. doi: 10.1097/CCM.0b013e3181d69ccf.CrossRefPubMedGoogle Scholar
  57. 57.
    Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis. J Med Assoc Thai. 2009;92(5):632–7.PubMedGoogle Scholar
  58. 58.
    MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174(4):564–74. doi: 10.1001/jamainternmed.2013.14673.CrossRefPubMedGoogle Scholar
  59. 59.
    Barletta JF. Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock. Ann Pharmacother. 2014;48(10):1276–81. doi: 10.1177/1060028014540513.CrossRefPubMedGoogle Scholar
  60. 60.
    Faisy C, Guerot E, Diehl JL, Iftimovici E, Fagon JY. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med. 2003;29(8):1306–13. doi: 10.1007/s00134-003-1863-3.CrossRefPubMedGoogle Scholar
  61. 61.
    Krag M, Perner A, Wetterslev J, Wise MP, Hylander Moller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40(1):11–22. doi: 10.1007/s00134-013-3125-3.CrossRefPubMedGoogle Scholar
  62. 62.
    Sasabuchi Y, Matsui H, Lefor AK, Fushimi K, Yasunaga H. Risks and benefits of stress ulcer prophylaxis for patients with severe sepsis. Crit Care Med. 2016;44(7):e464–9. doi: 10.1097/ccm.0000000000001667.CrossRefPubMedGoogle Scholar
  63. 63.
    Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med. 2016;44(10):1842–50. doi: 10.1097/ccm.0000000000001819.CrossRefPubMedGoogle Scholar
  64. 64.
    Alhazzani W, Guyatt G, Alshahrani M, Deane AM, Marshall JC, Hall R, Muscedere J, English SW, Lauzier F, Thabane L, Arabi YM, Karachi T, Rochwerg B, Finfer S, Daneman N, Alshamsi F, Zytaruk N, Heel-Ansdell D, Cook D. Withholding pantoprazole for stress ulcer prophylaxis in critically Ill patients: a pilot randomized clinical trial and meta-analysis. Crit Care Med. 2017;45(7):1121–9. doi: 10.1097/ccm.0000000000002461.CrossRefPubMedGoogle Scholar
  65. 65.
    Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, Pelosi P, Keus F, Guttormsen AB, Schefold JC, Moller MH. Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial. Trials. 2016;17(1):205. doi: 10.1186/s13063-016-1331-3.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Stress Ulcer Prophylaxis in the Intensive Care Unit. [cited 2017 Aug 1]. www.sup-icu.com.
  67. 67.
    Schefold J. Sup-Icu RENal (SIREN)—a sub-analysis of the prospective SUP-ICU trial on the risk of GI-bleeding in ICU patients receiving renal replacement therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2017 Aug 1]. https://clinicaltrials.gov/ct2/show/study/NCT02718261?cond=stress+ulcer&draw=1&rank=15. NLM Identifier: NCT02718261.
  68. 68.
    Young P. A multi-centre, cluster randomised, crossover, registry trial comparing the safety and efficacy of proton pump inhibitors with histamine-2 receptor blockers for ulcer prophylaxis in intensive care patients requiring invasive mechanical intervention. In: Australian and New Zealand Clinical Trials Registry [Internet]: Sydney (NSW): National Health and Medical Research Council (Australia). 2005—[cited 2017 Aug 1]. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370438&isReview=true Identifier ACTRN12616000481471.
  69. 69.
    Hurt RT, Frazier TH, McClave SA, Crittenden NE, Kulisek C, Saad M, Franklin GA. Stress prophylaxis in intensive care unit patients and the role of enteral nutrition. JPEN J Parenter Enteral Nutr. 2012;36(6):721–31. doi: 10.1177/0148607112436978.CrossRefPubMedGoogle Scholar
  70. 70.
    MacLaren R, Jarvis CL, Fish DN. Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother. 2001;35(12):1614–23.CrossRefPubMedGoogle Scholar
  71. 71.
    Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010;38(11):2222–8. doi: 10.1097/CCM.0b013e3181f17adf.CrossRefPubMedGoogle Scholar
  72. 72.
    Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54(11):2312–7. doi: 10.1007/s10620-009-0951-9.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–22.CrossRefPubMedGoogle Scholar
  74. 74.
    Azevedo J, Soares M, Silva G. Prevention of stress ulcer bleeding in high risk patients. Comparison of three drugs. Gastrenterologia Endosc. Dig. 2000;19:239–44.Google Scholar
  75. 75.
    Bashar FR, Manuchehrian N, Mahmoudabadi M, Hajiesmaeili MR, Torabian S. Effects of ranitidine and pantoprazole on ventilator-associated pneumonia: a randomized double-blind clinical trial. Tanaffos. 2013;12(2):16–21.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Solouki M, Mar’ashian SM, Koochak M, Nasiri A, Mokhtari M, Amirpour A. Ventilator-associated pneumonia among ICU patients receiving mechanical ventilation and prophylaxis of gastrointestinal bleeding. Iranian J. Clin. Infect. Dis. 2009;4(3):177–80.Google Scholar
  77. 77.
    Somberg L, Morris J Jr, Fantus R, Graepel J, Field BG, Lynn R, Karlstadt R. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma. 2008;64(5):1202–10. doi: 10.1097/TA.0b013e31815e40b5.CrossRefPubMedGoogle Scholar
  78. 78.
    Alquraini M, Alshamsi F, Moller MH, Belley-Cote E, Almenawer S, Jaeschke R, MacLaren R, Alhazzani W. Sucralfate versus histamine 2 receptor antagonists for stress ulcer prophylaxis in adult critically ill patients: a meta-analysis and trial sequential analysis of randomized trials. J Crit Care. 2017;40:21–30. doi: 10.1016/j.jcrc.2017.03.005.CrossRefPubMedGoogle Scholar
  79. 79.
    Cook DJ, Laine LA, Guyatt GH, Raffin TA. Nosocomial pneumonia and the role of gastric pH. A meta-analysis. Chest. 1991;100(1):7–13.CrossRefPubMedGoogle Scholar
  80. 80.
    Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275(4):308–14.CrossRefPubMedGoogle Scholar
  81. 81.
    Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–9. doi: 10.1503/cmaj.092129.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Huang J, Cao Y, Liao C, Wu L, Gao F. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care. 2010;14(5):R194. doi: 10.1186/cc9312.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321(7269):1103–6.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Tryba M. Prophylaxis of stress ulcer bleeding. A meta-analysis. J Clin Gastroenterol. 1991;13(Suppl 2):S44–55.PubMedGoogle Scholar
  85. 85.
    Tryba M. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. Crit Care Med. 1991;19(7):942–9.CrossRefPubMedGoogle Scholar
  86. 86.
    Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ. 2013;347:f5416. doi: 10.1136/bmj.f5416.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Momosaki R, Yasunaga H, Matsui H, Fushimi K, Abo M. Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis. 2016;25(5):1035–40. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.018.CrossRefPubMedGoogle Scholar
  88. 88.
    Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8. doi: 10.1001/jama.2009.722.CrossRefPubMedGoogle Scholar
  89. 89.
    Arai N, Nakamizo T, Ihara H, Koide T, Nakamura A, Tabuse M, Miyazaki H. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. PLoS ONE. 2017;12(1):e0169300. doi: 10.1371/journal.pone.0169300.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N, Feng W, Kumar S. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712–8. doi: 10.1002/ana.24262.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Ran L, Khatibi NH, Qin X, Zhang JH. Proton pump inhibitor prophylaxis increases the risk of nosocomial pneumonia in patients with an intracerebral hemorrhagic stroke. Acta Neurochir Suppl. 2011;111:435–9. doi: 10.1007/978-3-7091-0693-8_75.CrossRefPubMedGoogle Scholar
  92. 92.
    Karanika S, Paudel S, Zervou FN, Grigoras C, Zacharioudakis IM, Mylonakis E. Prevalence and clinical outcomes of clostridium difficile infection in the intensive care unit: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3(1):ofv186. doi: 10.1093/ofid/ofv186.CrossRefPubMedGoogle Scholar
  93. 93.
    Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308–13. doi: 10.1111/j.1572-0241.2008.01975.x.CrossRefPubMedGoogle Scholar
  94. 94.
    Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton pump inhibitors and the risk for hospital-acquired clostridium difficile infection. Mayo Clin Proc. 2013;88(10):1085–90. doi: 10.1016/j.mayocp.2013.07.004.CrossRefPubMedGoogle Scholar
  95. 95.
    Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired clostridium difficile infection in critically ill patients. Crit Care. 2014;18(6):714. doi: 10.1186/s13054-014-0714-7.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Beaulieu M, Williamson D, Pichette G, Lachaine J. Risk of clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol. 2007;28(11):1305–7. doi: 10.1086/521664.CrossRefPubMedGoogle Scholar
  97. 97.
    Buendgens L, Bruensing J, Matthes M, Duckers H, Luedde T, Trautwein C, Tacke F, Koch A. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014;29(4):696-e611. doi: 10.1016/j.jcrc.2014.03.002.CrossRefGoogle Scholar
  98. 98.
    Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243–5.CrossRefPubMedGoogle Scholar
  99. 99.
    Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther. 2009;29(6):626–34. doi: 10.1111/j.1365-2036.2008.03924.x.CrossRefPubMedGoogle Scholar
  100. 100.
    Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33–8.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Dubberke ER, Yan Y, Reske KA, Butler AM, Doherty J, Pham V, Fraser VJ. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol. 2011;32(4):360–6. doi: 10.1086/658944.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90. doi: 10.1001/archinternmed.2010.89.CrossRefPubMedGoogle Scholar
  103. 103.
    Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci. 2007;37(3):241–7.PubMedGoogle Scholar
  104. 104.
    Lewis PO, Litchfield JM, Tharp JL, Garcia RM, Pourmorteza M, Reddy CM. Risk and severity of hospital-acquired clostridium difficile infection in patients taking proton pump inhibitors. Pharmacotherapy. 2016;36(9):986–93. doi: 10.1002/phar.1801.CrossRefPubMedGoogle Scholar
  105. 105.
    Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273–80. doi: 10.1086/502539.CrossRefPubMedGoogle Scholar
  106. 106.
    Nath SK, Salama S, Persaud D, Thornley JH, Smith I, Foster G, Rotstein C. Drug risk factors associated with a sustained outbreak of Clostridium difficile diarrhea in a teaching hospital. Can J Infect Dis. 1994;5(6):270–5.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Pakyz AL, Jawahar R, Wang Q, Harpe SE. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres. J Antimicrob Chemother. 2014;69(4):1127–31. doi: 10.1093/jac/dkt489.CrossRefPubMedGoogle Scholar
  108. 108.
    Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28(4):377–81. doi: 10.1086/513723.CrossRefPubMedGoogle Scholar
  109. 109.
    Shaughnessy MK, Micielli RL, DePestel DD, Arndt J, Strachan CL, Welch KB, Chenoweth CE. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2011;32(3):201–6. doi: 10.1086/658669.CrossRefPubMedGoogle Scholar
  110. 110.
    Southern WN, Rahmani R, Aroniadis O, Khorshidi I, Thanjan A, Ibrahim C, Brandt LJ. Postoperative Clostridium difficile-associated diarrhea. Surgery. 2010;148(1):24–30. doi: 10.1016/j.surg.2009.11.021.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf. 2011;20(10):1035–42. doi: 10.1002/pds.2198.CrossRefPubMedGoogle Scholar
  112. 112.
    Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther. 2006;24(4):613–9. doi: 10.1111/j.1365-2036.2006.03015.x.CrossRefPubMedGoogle Scholar
  113. 113.
    Arriola V, Tischendorf J, Musuuza J, Barker A, Rozelle JW, Safdar N. Assessing the risk of hospital-acquired clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol. 2016;37(12):1408–17. doi: 10.1017/ice.2016.194.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9. doi: 10.1038/ajg.2012.108.CrossRefPubMedGoogle Scholar
  115. 115.
    Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55. doi: 10.1086/651706.CrossRefPubMedGoogle Scholar
  116. 116.
    Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;. doi: 10.1001/jamainternmed.2017.0212.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Cawley MJ, Wittbrodt ET, Boyce EG, Skaar DJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19(1):108–13.CrossRefPubMedGoogle Scholar
  118. 118.
    Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139(2):271–8. doi: 10.1378/chest.10-2243.CrossRefPubMedGoogle Scholar
  119. 119.
    Shalansky SJ, Verma AK, Levine M, Spinelli JJ, Dodek PM. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy. 2002;22(7):803–13.CrossRefPubMedGoogle Scholar
  120. 120.
    Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, Crowther M, Warkentin TE, Dodek P, Cade J, Lesur O, Lim W, Fowler R, Lamontagne F, Langevin S, Freitag A, Muscedere J, Friedrich JO, Geerts W, Burry L, Alhashemi J, Cook D. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207–15. doi: 10.1378/chest.13-0121.CrossRefPubMedGoogle Scholar
  121. 121.
    Williamson DR, Lesur O, Tetrault JP, Pilon D. Drug-induced thrombocytopenia in the critically ill: a case-control study. Ann Pharmacother. 2014;48(6):697–704. doi: 10.1177/1060028013519065.CrossRefPubMedGoogle Scholar
  122. 122.
    Wade EE, Rebuck JA, Healey MA, Rogers FB. H(2) antagonist-induced thrombocytopenia: is this a real phenomenon? Intensive Care Med. 2002;28(4):459–65. doi: 10.1007/s00134-002-1233-6.CrossRefPubMedGoogle Scholar
  123. 123.
    Henann NE, Carpenter DU, Janda SM. Famotidine-associated mental confusion in elderly patients. Drug Intell Clin Pharm. 1988;22(12):976–8.CrossRefPubMedGoogle Scholar
  124. 124.
    Odeh M, Oliven A. Central nervous system reactions associated with famotidine: report of five cases. J Clin Gastroenterol. 1998;27(3):253–4.CrossRefPubMedGoogle Scholar
  125. 125.
    Barkun AN, Adam V, Martel M, Bardou M. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health. 2013;16(1):14–22. doi: 10.1016/j.jval.2012.08.2213.CrossRefPubMedGoogle Scholar
  126. 126.
    Hammond DA, Kathe N, Shah A, Martin BC. Cost-effectiveness of Histamine2 receptor antagonists versus proton pump inhibitors for stress ulcer prophylaxis in critically Ill patients. Pharmacotherapy. 2017;37(1):43–53. doi: 10.1002/phar.1859.CrossRefPubMedGoogle Scholar
  127. 127.
    MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*. Crit Care Med. 2014;42(4):809–15. doi: 10.1097/ccm.0000000000000032.CrossRefPubMedGoogle Scholar
  128. 128.
    Udeh BL, Udeh C, Hata JS. Cost-effectiveness of stress ulcer prophylaxis: role of proton pump inhibitors. Am J Pharm Benefits. 2010;2(5):304–12.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Jeffrey F. Barletta
    • 1
  • Alicia J. Mangram
    • 2
  • Joseph F. Sucher
    • 2
  • Victor Zach
    • 3
  1. 1.Midwestern University, College of Pharmacy-GlendaleGlendaleUSA
  2. 2.Honor Health- John C. Lincoln Medical CenterPhoenixUSA
  3. 3.Honor HealthA.T. Still University School of Osteopathic MedicinePhoenixUSA

Personalised recommendations